These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12388634)

  • 1. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.
    Osborn BL; Olsen HS; Nardelli B; Murray JH; Zhou JX; Garcia A; Moody G; Zaritskaya LS; Sung C
    J Pharmacol Exp Ther; 2002 Nov; 303(2):540-8. PubMed ID: 12388634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.
    Sung C; Nardelli B; LaFleur DW; Blatter E; Corcoran M; Olsen HS; Birse CE; Pickeral OK; Zhang J; Shah D; Moody G; Gentz S; Beebe L; Moore PA
    J Interferon Cytokine Res; 2003 Jan; 23(1):25-36. PubMed ID: 12639296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV.
    Flores MV; Hickling TP; Sreckovic S; Fidock MD; Horscroft N; Katragadda M; Savic B; Rawal J; Delpuech-Adams OE; Robas N; Corey T; Nelms L; Lawton M; Marcek J; Stubbs M; Westby M; Ciaramella G
    Antivir Ther; 2012; 17(5):869-81. PubMed ID: 22505586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
    Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
    Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Post AB; Redfield RR; Davis GL; Neumann AU; Osborn BL; Freimuth WW; Subramanian GM
    Antivir Ther; 2006; 11(1):35-45. PubMed ID: 16518958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basis for dosing time-dependent changes in the antiviral activity of interferon-alpha in mice.
    Ohdo S; Wang DS; Koyanagi S; Takane H; Inoue K; Aramaki H; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 2000 Aug; 294(2):488-93. PubMed ID: 10900223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
    Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
    Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C.
    Rustgi VK
    Curr Med Res Opin; 2009 Apr; 25(4):991-1002. PubMed ID: 19275518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
    BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug evaluation: Albuferon-alpha--an antiviral interferon-alpha/albumin fusion protein.
    Chemmanur AT; Wu GY
    Curr Opin Investig Drugs; 2006 Aug; 7(8):750-8. PubMed ID: 16955687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HM10660A, a long-acting hIFN-α-2b, is a potent candidate for the treatment of hepatitis C through an enhanced biological half-life.
    Bae S; Sim T; Lim C; Kim D; Lee J; Park Y; Jung S; Choi I; Kwon S; Oh KT
    Int J Pharm; 2017 Dec; 534(1-2):89-96. PubMed ID: 28982547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
    Brennan BJ; Xu ZX; Grippo JF
    Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
    Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C.
    Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Garcia A; Moore PA; Yu R; Subramanian GM
    Antivir Ther; 2006; 11(7):901-8. PubMed ID: 17302252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs.
    Yuan L; Wang J; Shen WC
    J Control Release; 2008 Jul; 129(1):11-7. PubMed ID: 18448186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
    Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
    J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
    De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
    J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dosing schedule on pharmacokinetics of alpha interferon and anti-alpha interferon neutralizing antibody in mice.
    Wang DS; Ohdo S; Koyanagi S; Takane H; Aramaki H; Yukawa E; Higuchi S
    Antimicrob Agents Chemother; 2001 Jan; 45(1):176-80. PubMed ID: 11120962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.
    Bain VG; Kaita KD; Yoshida EM; Swain MG; Heathcote EJ; Neumann AU; Fiscella M; Yu R; Osborn BL; Cronin PW; Freimuth WW; McHutchison JG; Subramanian GM
    J Hepatol; 2006 Apr; 44(4):671-8. PubMed ID: 16487617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
    Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
    Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.